MX2023005896A - Variantes de anticuerpos bovinos. - Google Patents

Variantes de anticuerpos bovinos.

Info

Publication number
MX2023005896A
MX2023005896A MX2023005896A MX2023005896A MX2023005896A MX 2023005896 A MX2023005896 A MX 2023005896A MX 2023005896 A MX2023005896 A MX 2023005896A MX 2023005896 A MX2023005896 A MX 2023005896A MX 2023005896 A MX2023005896 A MX 2023005896A
Authority
MX
Mexico
Prior art keywords
variants
bovine antibodies
bovine
bovine antibody
antibodies
Prior art date
Application number
MX2023005896A
Other languages
English (en)
Spanish (es)
Inventor
Sandra Ann Marie Lightle
Henry Luis Campos
Catherine J Strietzel
Yaqi Zhu
Gregory John Fici
Alexander Pogacsas Ruhland Bally
Prajna Shanbhogue
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2023005896A publication Critical patent/MX2023005896A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2023005896A 2020-11-20 2021-11-19 Variantes de anticuerpos bovinos. MX2023005896A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063116491P 2020-11-20 2020-11-20
PCT/US2021/060161 WO2022109313A1 (en) 2020-11-20 2021-11-19 Bovine antibody variants

Publications (1)

Publication Number Publication Date
MX2023005896A true MX2023005896A (es) 2023-07-03

Family

ID=79018979

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005896A MX2023005896A (es) 2020-11-20 2021-11-19 Variantes de anticuerpos bovinos.

Country Status (12)

Country Link
US (1) US20230416410A1 (https=)
EP (1) EP4247851A1 (https=)
JP (1) JP2023551194A (https=)
KR (1) KR20230110297A (https=)
CN (1) CN116615463A (https=)
AR (1) AR124130A1 (https=)
AU (1) AU2021382704A1 (https=)
BR (1) BR112023008490A2 (https=)
CA (1) CA3202089A1 (https=)
CO (1) CO2023007146A2 (https=)
MX (1) MX2023005896A (https=)
WO (1) WO2022109313A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255933A4 (en) 2020-12-07 2025-07-23 Invetx Inc COMPOSITIONS FOR INCREASING THE HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USE
CN119730881A (zh) * 2022-08-05 2025-03-28 硕腾服务有限责任公司 牛抗体突变体
JP2025529206A (ja) * 2022-09-02 2025-09-04 ゾエティス・サービシーズ・エルエルシー 豚抗体変異体
CN119735654B (zh) * 2025-02-27 2025-07-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2984405T3 (es) * 2012-09-13 2024-10-29 Bristol Myers Squibb Co Proteínas de dominio de andamio basadas en fibronectina que se unen a la miostatina
US11891440B2 (en) * 2015-10-05 2024-02-06 Circle33 Llc Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease

Also Published As

Publication number Publication date
KR20230110297A (ko) 2023-07-21
AR124130A1 (es) 2023-02-15
AU2021382704A9 (en) 2025-03-27
WO2022109313A1 (en) 2022-05-27
CO2023007146A2 (es) 2023-06-30
CA3202089A1 (en) 2022-05-27
JP2023551194A (ja) 2023-12-07
CN116615463A (zh) 2023-08-18
US20230416410A1 (en) 2023-12-28
AU2021382704A1 (en) 2023-06-08
EP4247851A1 (en) 2023-09-27
BR112023008490A2 (pt) 2023-12-12

Similar Documents

Publication Publication Date Title
MX2023005896A (es) Variantes de anticuerpos bovinos.
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
SA521420953B1 (ar) بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1
WO2019224716A8 (en) Antibodies specific for gucy2c and uses thereof
MX2023008785A (es) Mutaciones en regiones constantes de anticuerpos caninos.
JOP20220161A1 (ar) جسم مضاد لـ lilrb1 واستخداماته
PH12022552742A1 (en) Canine antibody variants
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
MX2023014154A (es) Anticuerpos anti-ccr8.
CL2023001052A1 (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
PH12022552743A1 (en) Feline antibody variants
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA202192810A1 (ru) АНТИТЕЛА К PcrV, КОТОРЫЕ СВЯЗЫВАЮТ PcrV, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К PcrV, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CL2024001519A1 (es) Mutaciones en regiones constantes de anticuerpos felinos.
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
MA43717B1 (fr) Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
EA201792329A1 (ru) Способ мономеризации рекомбинантных молекул антител
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
WO2022067233A3 (en) Canine antibody variants
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
EP4711383A3 (en) Feline antibody variants